The drug Hydroxychloroquine is only being given to doctors and contacts of lab confirmed COVID-19 cases, senior scientist at ICMR Raman R Gangakhedkar said on Tuesday stressing that it is not to be taken by everyone.
Hydroxychloroquine has been described as an essential drug by Health Ministry to meet the requirements of any emergency arising due to COVID-19 pandemic and its sale and distribution have been restricted.
When asked about ICMR's official position on use of Hydroxychloroquine amid various contradicting reports about it, Gangakhedkar, Head of Epidemiology and Communicable diseases at the medical research body, said the organisation has repeatedly conveyed that it is not recommended to be used by everyone.
We have repeatedly said it is not to be used by everyone. It is being given to doctors and contacts of lab confirmed cases. When their data will be complied only then a call can be taken whether it should be recommended to everyone (who is at risk), he said.
ICMR has already recommended the use of hydroxychloroquine as a preventive medication for healthcare workers involved in the care of suspected or confirmed cases of COVID-19 and also asymptomatic household contacts of laboratory confirmed cases.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app